Celladon Corporation’s CLDN shares plummeted 80.7% following the company’s announcement that randomized, double-blind, placebo-controlled, multinational phase IIb study (CUPID2) on advanced heart ...
Celladon said yesterday its lead investigational product candidate, the cardiovascular gene therapy agent Mydicar® (AAV1/SERCA2a), did not meet its primary and secondary endpoints in the Phase IIb ...
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Thinkstock On its website, Celladon Corp. (NASDAQ: CLDN) ...
(Reuters) - Drug developer Celladon Corp said it expected to announce lay-offs and cost cuts as its stock plunged to an all-time low after the company's lead experimental gene therapy to treat heart ...
SAN DIEGO, June 1, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), today announced that its Board of Directors has unanimously approved a strategic plan pursuant to which the Company will ...
SAN DIEGO, April 26, 2015 -- Celladon Corporation (CLDN) today announced that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints. CUPID2 is a randomized, double-blind, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results